Rheumatoid Arthritis and Hyperbaric Oxygen Therapy
Nippon Seikeigeka Gakkai Zasshi, 1985, Jan, 59(1):17-26
“Superoxide dismutase and Hyperbaric Oxygen Therapy for the patient with rheumatoid arthritis.”Kamada, T.
Cu, Zn-SOD values were measured by enzyme immunoassay in the synovial fluid, leukocytes in the synovial fluid, synovial membrane, and leukocytes in the blood of patients with rheumatoid arthritis. SOD activity, lipoperoxide value in serum, ESR, and Lansbury’s index of the patients with rheumatoid arthritis under Hyperbaric Oxygen Therapy (HBOT) were also investigated. SOD values of synovial fluid and of leukocytes in synovial fluid from the rheumatoid arthritis group were found to be higher than those from the osteoarthritis group. No significant difference was found in the SOD values in leukocytes of blood and synovial membrane between the two groups.
In the patients with rheumatoid arthritis under HBOT therapy the SOD activity was increased, whereas lipoperoxide values were decreased. Furthermore, ESR and Lansbury’s index showed a remarkable recovery.
These results suggest that HBOT therapy may be an effective treatment for patients with rheumatoid arthritis.
Wallace, Goldberg et. ,al.
Hyperbaric Oxygen Therapy on Auto Immune disorders Lupus Journal 1996
The Text Book of Hyperbaric Oxygen Therapy, Vol 1,2,3K.K. Jain MD
Hyperbaric Oxygen Therapy In The Treatment Of Post-Menopausal Osteoporosis
Sparacia B., Sparacia G., Sansone A.
A vast amount of research has shown that hyperbaric oxygen therapy has the capacity to reactivate
osteogenetic cells which are metabolically quiescent.
This has been shown in experimental osteoporosis, and in the repair of fractures, both in man and
in animals. Its effectiveness in the therapy of post-menopausal osteoporosis has, however, less
The aim of our work has been to show the role played by H.O.T. in the treatment of this pathology,
and its synergic action when associated with a specific pharmacological treatment.
Material and methods
Files were collected of 60 female patients in menopause, between the ages of 50 and 65,
suffering from osteoporosis diagnosed and documented through bone densitometry? Women with chronic
renal insufficiency, endocrine diseases, those undergoing therapies which might influence bone
metabolism, and those with cardiopulmonary disorders were excluded. The patients were divided at
random into four sub groups of 15 people to each group.
Group A – Treatment with HOT – 20 treatments a day 1.8 ATA lasting 90 minutes. Three month cycles
(one month of treatment, 2 months suspension 8 cycles of therapy).
x Group B – Treatment with calcitonina – Therapy with only calcitonina (100 U.I./die)
x 8 cycles of 3 months, with intervals of 2 months without therapy.
x Group C – Associated treatment – Treatment HOT with calcitonina, using the same
x procedure as groups A and B.
x Group D – Control group – No specific treatment.
For the therapy with calcitonina, salmon calcitonina in spray solution was used (Armour). Daily
dosage – 100 U.I./die. Before the beginning of very treatment, then every three months until the
end of the complete procedure, (24 months), all the patients underwent examination with instruments
and in laboratory: 1) bone densitometry taken on the proximal and (?) of the radius (instrument
Norland 2600 using Gandolinio 150); 2) calciuria, idrossiprolinuria, fosfaturia; fosfatasi alcalina
For HOT treatments a hyperbaric chamber (?) Galeazzi was used more than one apparatus with space
for more than one patient.
The resulting data was analysed statistically according to Test t of Student for paired data.
Results-discussion Results obtained from the 4 groups did not show a significant variation in the
density of compact bone in all four groups. As far as trabecular bone was concerned, it was
possible toes: in group A a reduction of 1.45% (annual average) (p<0.05) of bone density; in group B an increase of 0.43% (annual average) of bone density - statistically not significant. In group Can increase of 2.3% (annual average) (p<0.05) of bone density. In group D (control group) a decrease of 3.04% (annual average) (p<0.1) of bone density. As far as biohumoral parameters (?) of bone density are concerned, no statistically significant differences are noted. Basing our common on these results, we can affirm that HOT produces a slowing down of the process of density loss in the treatment of post-menopausal osteoporosis. More significant, however, is shown to be the pharmacological association of HOT and calcitonina, which has resulted in a significant increase in density, and thus in bone mass. It is possible, therefore, to conclude that, in the treatment of post-menopausal osteoporosis, the association of calcitonina and HOT is that which, at the present moment, is able to produce the best results. [divider_line]
HBOT has brought quick and lasting pain relief for arthritis sufferers:
Hyperbaric oxygen treatment is comparable to acetylsalicylic acid treatment in an animal model of arthritis.
Wilson HD, Toepfer VE, Senapati AK, Wilson JR, Fuchs PN.
J Pain. 2007 Dec;8(12):924-30. Epub 2007 Aug 9.Department of Psychology,
University of Texas at Arlington, Arlington, Texas 76109, USA.
Approximately 1 in 5 adults in the United States are affected by the pain, disability, and decreased quality of life associated with arthritis. The primary focus of treatment is on reducing joint inflammation and pain through a variety of pharmacotherapies, each of which is associated with various side effects.
Hyperbaric oxygen therapy is an alternative treatment that has been recommended to treat a variety of inflammatory diseases, ranging from chronic brain injury to exercise induced muscle soreness. The purpose of this set of experiments was to explore the effect of hyperbaric oxygen therapy on joint inflammation and mechanical hyperalgesia in an animal model of arthritis, and compare these effects to treatment with aspirin. Hyperbaric oxygen therapy significantly reduced both joint inflammation and hyperalgesia. As compared with aspirin treatment, hyperbaric treatment was equally as effective in decreasing joint inflammation and hyperalgesia.
PERSPECTIVE: This article reports that hyperbaric oxygen treatment decreases pain and inflammation in an animal model of arthritis. The effect of hyperbaric oxygen treatment is very similar in magnitude to the effect of acetylsalicylic acid treatment.
Potentially, hyperbaric oxygen could be used to treat pain and inflammation in patients with arthritis.
Place of hemocarboperfusion and hyperbaric oxygenation in the treatment of patients with rheumatoid arthritis with systemic symptoms
Saikovskii RS, Alekberova ZS, Dmitriev AA, Ashurova LL, Mach ES.
Altogether 12 patients were treated by the hemocarboperfusion method and 20 patients with systemic symptoms by the hyperbaric oxygenation (HBO) method. Positive results were obtained and it made it possible to recommend the above methods for multimodality therapy of patients with rheumatoid arthritis with systemic symptoms. A severe, rapidly progressive course of rheumatoid arthritis with the development of various systemic symptoms, a high titer of the rheumatoid factor should serve as an indication for hemocarboperfusion. HBO is found appropriate in such systemic symptoms as ischemic polyneuropathy, digital arteritis, trophic ulcers and Raynaud’s syndrome.
Hyperbaric oxygenation in the comprehensive therapy of patients with rheumatoid arthritis
(clinico-immunologic study) Lukich VL, Poliakova LV, Sotnikova TI, Belokrinitski? DV.
Fiziol Zh. 1991 Sep-Oct;37(5):55-60.
For 35 of 50 patients with rheumatoid arthritis traditional drug therapy was a minor success for a long time. Without any modifications of the drug therapy every patient went through a course of hyperbaric oxygenation (HBO): 21 sessions under 1.7 ATA for 40 min. Good clinical results both immediate and remote have been obtained. The effect of HBO on the immune system of the patients has intensified the suppressive function of T-lymphocytes (especially with systemic symptoms of the disease), normalized cell-bound immunity and decreased the serum concentration in immune complexes.